Fungal Infections in Transplant and Oncology Patients
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Recent shifts in the epidemiology of invasive fungal infections (IFIs) among transplant and oncology populations have led to new recommendations on treatment; however, they have also brought new controversies. New pharmacologic therapies are being studied and guidelines for management of several IFIs have been changed accordingly. More information is being discovered about unique genetic factors that put some transplant recipients at greater risk than others for fungal infection. The role of immunomodulation continues to be investigated, and the delicate balance of maintaining some immune integrity while assuring protection of the graft remains critical. For transplant and oncology patients, the diagnosis and management of IFIs remain challenging, and improving outcomes depends on continued progress in all of these arenas. This article highlights recent advances and important factors to consider when treating transplant and oncology patients with IFIs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191
Aspergillus fumigatus and Aspergillosis
Latgé, J.-P. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.2.310 · Cited by 2,307 · cited 1×
“Aspergillus fumigatus is the most frequent species of Aspergillus causing clinical disease, perhaps due to specific virulence factors unique to the organism [13].”
BackgroundComparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Attributable Mortality of Nosocomial Candidemia, Revisited
Gudlaugsson, O., Gillespie, S., Lee, K., Berg, J. V., Hu, J., Messer, S., Herwaldt, L., Pfaller, M., & Diekema, D. (2003) · Clinical Infectious Diseases · doi:10.1086/378745 · Cited by 1,140
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039
Horn, D. L., Neofytos, D., Anaissie, E. J., Fishman, J. A., Steinbach, W. J., Olyaei, A. J., Marr, K. A., Pfaller, M. A., Chang, C., & Webster, K. M. (2009) · Clinical Infectious Diseases · doi:10.1086/599039 · Cited by 956 · cited 1×
“albicans remains the most frequently isolated Candida species among SOT recipients, a shift towards more non-albicans Candida infections seems to be occurring in this population as well [28].”
BackgroundAnidulafungin versus Fluconazole for Invasive Candidiasis
Reboli, A. C., Rotstein, C., Pappas, P. G., Chapman, S. W., Kett, D. H., Kumar, D., Betts, R., Wible, M., Goldstein, B. P., Schranz, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066906 · Cited by 894
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
Denning, D. W., Ribaud, P., Milpied, N., Caillot, D., Herbrecht, R., Thiel, E., Haas, A., Ruhnke, M., & Lode, H. (2002) · Clinical Infectious Diseases · doi:10.1086/324620 · Cited by 844 · cited 1×
“Because of these issues, voriconazole levels should be monitored during therapy [95].”
BackgroundNeofytos, D., Horn, D., Anaissie, E., Steinbach, W., Olyaei, A., Fishman, J., Pfaller, M., Chang, C., Webster, K., & Marr, K. (2009) · Clinical Infectious Diseases · doi:10.1086/595846 · Cited by 801
Kuse, E.-R., Chetchotisakd, P., da Cunha, C. A., Ruhnke, M., Barrios, C., Raghunadharao, D., Sekhon, J. S., Freire, A., Ramasubramanian, V., Demeyer, I., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60605-9 · Cited by 692
Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality.
Fraser, V. J., Jones, M., Dunkel, J., Storfer, S., Medoff, G., & Dunagan, W. C. (1992) · Clinical Infectious Diseases · doi:10.1093/clind/15.3.414 · Cited by 679
Importance of Candida Species Other than C. albicans as Pathogens in Oncology Patients
Wingard, J. R. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/20.1.115 · Cited by 542 · cited 1×
“The routine use of azole prophylaxis in high risk cancer populations has certainly contributed to the decreased incidence of IC in these populations [24,25] and likely accounts in part for the increasing frequency of non-albicans Candida infections [23,26,27].”
BackgroundKullberg, B., Sobel, J., Ruhnke, M., Pappas, P., Viscoli, C., Rex, J., Cleary, J., Rubinstein, E., Church, L., Brown, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67490-9 · Cited by 521
Rex, J. H., Pappas, P. G., Karchmer, A. W., Sobel, J., Edwards, J. E., Hadley, S., Brass, C., Vazquez, J. A., Chapman, S. W., Horowitz, H. W., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/374850 · Cited by 495
Fukuda, T., Boeckh, M., Carter, R. A., Sandmaier, B. M., Maris, M. B., Maloney, D. G., Martin, P. J., Storb, R. F., & Marr, K. A. (2003) · Blood · doi:10.1182/blood-2003-02-0456 · Cited by 465
The Impact of Culture Isolation of Aspergillus Species: A Hospital‐Based Survey of Aspergillosis
Perfect, J. R., Cox, G. M., Lee, J. Y., Kauffman, C. A., de Repentigny, L., Chapman, S. W., Morrison, V. A., Pappas, P., Hiemenz, J. W., Stevens, D. A., et al. (2001) · Clinical Infectious Diseases · doi:10.1086/323900 · Cited by 458 · cited 1×
“In contrast, recovery of Aspergillus from lower respiratory tract specimens in patients with hematologic malignancy or undergoing HSCT has a high positive predictive value for invasive disease [21].”
BackgroundToll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation
Bochud, P.-Y., Chien, J. W., Marr, K. A., Leisenring, W. M., Upton, A., Janer, M., Rodrigues, S. D., Li, S., Hansen, J. A., Zhao, L. P., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802629 · Cited by 453 · cited 1×
“Recently, studies in HSCT populations have shown that polymorphisms in Toll-like receptor 4 [82] and genetic variations within the plasminogen allele may influence susceptibility to IA after transplant [83].”
BackgroundDeterminants of Disease Presentation and Outcome during Cryptococcosis: The CryptoA/D Study
Dromer, F., Mathoulin-Pélissier, S., Launay, O., Lortholary, O., & the French Cryptococcosis Study Group (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040021 · Cited by 374
Sipsas, N. V., Lewis, R. E., Tarrand, J., Hachem, R., Rolston, K. V., Raad, I. I., & Kontoyiannis, D. P. (2009) · Cancer · doi:10.1002/cncr.24507 · Cited by 269 · cited 2×
“Similarly, between 2001 and 2007 at MD Anderson Cancer Center, non-albicans Candida species were responsible for 75% of IC cases occurring in patients with hematologic malignancy or undergoing HSCT [23].”
BackgroundSelf-citationRisk Factors for Disseminated or Fatal Histoplasmosis: Analysis of a Large Urban Outbreak
WHEAT, L. J., SLAMA, T. G., NORTON, J. A., KOHLER, R. B., EITZEN, H. E., FRENCH, M. L. V., & SATHAPATAYAVONGS, B. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-96-2-159 · Cited by 196 · cited 1×
“Further, among immunosuppressed patients with histoplasmosis, 74% had fatal or disseminated infections compared with 7% of patients who were not immunosuppressed [57].”
BackgroundCaillot, D., Thiébaut, A., Herbrecht, R., de Botton, S., Pigneux, A., Bernard, F., Larché, J., Monchecourt, F., Alfandari, S., & Mahi, L. (2007) · Cancer · doi:10.1002/cncr.23109 · Cited by 190
Cited by
Kontoyiannis, D. P., Yang, H., Song, J., Kelkar, S. S., Yang, X., Azie, N., Harrington, R., Fan, A., Lee, E., & Spalding, J. R. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-2023-z · Cited by 132
“Due to lack of time stamps of the drug prescriptions, it was not clear if these fluconazole and voriconazole prescriptions were intended to treat mucormycosis or were intended to serve as prophylaxis treatment for patients with high risk of various invasive fungal infections, such as patients with leukemia and recipie…”
BackgroundSelf-citationMethods of Controlling Invasive Fungal Infections Using CD8+ T Cells
Kumaresan, P. R., da Silva, T. A., & Kontoyiannis, D. P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01939 · Cited by 85
Self-citationCellular therapy for multiple pathogen infections after hematopoietic stem cell transplant
Sutrave, G., Blyth, E., & Gottlieb, D. J. (2017) · Cytotherapy · doi:10.1016/j.jcyt.2017.07.012 · Cited by 20
Metadata
- Authors
- Person, A. K., Kontoyiannis, D. P., & Alexander, B. D.
- Venue
- Infectious Disease Clinics of North America
- Publisher
- Elsevier BV
- Published
- 2010-06
- Volume
- 24
- Issue
- 2
- Pages
- 439-459
- ISSN
- 0891-5520 (ISSN-L)
- OpenAlex
- W1988042170
- Cited by
- 61
- References
- 22
- FWCI
- 4.23
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.